| Literature DB >> 30340182 |
Edward F Pace-Schott1, Ryan M Bottary2, Se-Yun Kim3, Peter L Rosencrans3, Shilpa Vijayakumar3, Scott P Orr3, Natasha B Lasko3, Elizabeth M Goetter3, Amanda W Baker3, Matt T Bianchi4, Karen Gannon4, Susanne S Hoeppner3, Stefan G Hofmann5, Naomi M Simon6.
Abstract
Exposure therapy for social anxiety disorder (SAD) utilizes fear extinction, a memory process enhanced by sleep. We investigated whether naps following exposure sessions might improve symptoms and biomarkers in response to social stress in adults undergoing 5-week exposure-based group SAD therapy. Thirty-two participants aged 18-39 (18 females) with SAD were randomized. Before and after treatment, participants completed the Liebowitz Social Anxiety Scale (LSAS) and underwent a Trier Social Stress Test with psychophysiological monitoring (mpTSST) that included skin conductance (SCL), electromyographic (EMG) and electrocardiographic recording, and an auditory startle procedure while anticipating the social stressor. At sessions 3 and 4, exposure was followed by either a 120-min polysomnographically monitored sleep opportunity (Nap, N = 17) or wakefulness (Wake, N = 15). Primary hypotheses about SAD symptom change (LSAS) and EMG blink-startle response failed to differ with naps, despite significant symptom improvement (LSAS) with therapy. Some secondary biomarkers, however, provided preliminary support for enhanced extinction learning with naps, with trend-level Time (pre-, post-treatment) × Arm interactions and significant reduction from pre- to post treatment in the Nap arm alone for mpTSST SCL and salivary cortisol rise. Because of the small sample size and limited sleep duration, additional well-powered studies with more robust sleep interventions are indicated.Entities:
Keywords: Cortisol; Exposure therapy; Extinction; Psychophysiology; Sleep; Social anxiety disorder
Mesh:
Substances:
Year: 2018 PMID: 30340182 PMCID: PMC6292728 DOI: 10.1016/j.psychres.2018.10.015
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222